10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
BRISTOL MYERS SQUIBB CO | ||
Ticker: BMY Fiscal Year: 2015 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2015 10-K (Filed: Feb 12, 2016) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2015 | Dec 31, 2014 | |
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 2,385 | 5,571 |
| Marketable securities, current | 1,885 | 1,864 |
| Receivables | 4,299 | 3,390 |
| Inventories | 1,221 | 1,560 |
| Deferred income taxes, current | 1,644 | |
| Prepaid expenses and other | 491 | 470 |
| Assets held-for-sale | 134 | 109 |
| Total Current Assets | 10,415 | 14,608 |
| Property, plant and equipment | 4,412 | 4,417 |
| Goodwill | 6,881 | 7,027 |
| Other intangible assets | 1,419 | 1,753 |
| Deferred income taxes | 2,844 | 915 |
| Marketable securities, noncurrent | 4,660 | 4,408 |
| Other assets | 1,117 | 621 |
| Total Assets | 31,748 | 33,749 |
| LIABILITIES | ||
| Current Liabilities: | ||
| Short-term borrowings | 139 | 590 |
| Accounts payable | 1,565 | 2,487 |
| Accrued expenses | 2,759 | 2,459 |
| Deferred income, current | 1,003 | 1,167 |
| Accrued rebates and returns | 1,324 | 851 |
| Income taxes payable, current | 572 | 262 |
| Dividends payable | 655 | 645 |
| Total Current Liabilities | 8,017 | 8,461 |
| Pension, postretirement, and postemployment liabilities | 949 | 1,115 |
| Deferred income, noncurrent | 586 | 770 |
| Income taxes payable, noncurrent | 742 | 560 |
| Other liabilities | 480 | 618 |
| Long-term debt | 6,550 | 7,242 |
| Total Liabilities | 17,324 | 18,766 |
| Commitments and contingencies (Note 22) | ||
| EQUITY | ||
| Bristol-Myers Squibb Company Shareholders' Equity: | ||
| Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 4,161 in 2015 and 4,212 in 2014, liquidation value of $50 per share | 0 | 0 |
| Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2015 and 2014 | 221 | 221 |
| Capital in excess of par value of stock | 1,459 | 1,507 |
| Accumulated other comprehensive loss | (2,468) | (2,425) |
| Retained earnings | 31,613 | 32,541 |
| Less cost of treasury stock - 539 million common shares in 2015 and 547 million in 2014 | (16,559) | (16,992) |
| Total Bristol-Myers Squibb Company Shareholders' Equity | 14,266 | 14,852 |
| Noncontrolling interest | 158 | 131 |
| Total Equity | 14,424 | 14,983 |
| Total Liabilities and Equity | 31,748 | 33,749 |
| External Links | |
| BRISTOL MYERS SQUIBB CO (BMY) Fiscal Year 2015 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |